261 related articles for article (PubMed ID: 16673277)
21. Atypical myeloproliferative disorders: diagnosis and management.
Tefferi A; Elliott MA; Pardanani A
Mayo Clin Proc; 2006 Apr; 81(4):553-63. PubMed ID: 16610578
[TBL] [Abstract][Full Text] [Related]
22. Myelofibrosis with myeloid metaplasia: the advanced phase of an untreated disseminated hematological cancer. Time to change our therapeutic attitude with early upfront treatment?
Hasselbalch HC
Leuk Res; 2009 Jan; 33(1):11-8. PubMed ID: 18632152
[TBL] [Abstract][Full Text] [Related]
23. Therapy for polycythemia vera and essential thrombocythemia is driven by the cardiovascular risk.
Barbui T; Finazzi G
Semin Thromb Hemost; 2007 Jun; 33(4):321-9. PubMed ID: 17525889
[TBL] [Abstract][Full Text] [Related]
24. Myelofibrosis--what's in a name? Consensus on definition and EUMNET grading.
Thiele J; Kvasnicka HM
Pathobiology; 2007; 74(2):89-96. PubMed ID: 17587880
[TBL] [Abstract][Full Text] [Related]
25. [The effectiveness of anagrelide treatment in patients with Ph negative myeloproliferative diseases: influence on the incidence of thrombosis in the data from the Registry of patients with essential thrombocythemia and thrombocythemia associated with other myeloproliferative diseases treated with Thromboreductin® to the end of 2012].
Penka M; Schwarz J; Ovesná P; Cervinek L; Dulíček P; Pospíšilová D; Kissová J; Pavlík T;
Vnitr Lek; 2013 Jun; 59(6):516-31. PubMed ID: 23808749
[TBL] [Abstract][Full Text] [Related]
26. The myeloproliferative disorders. An historical appraisal and personal experiences.
Michiels JJ
Leuk Lymphoma; 1996 Sep; 22 Suppl 1():1-14. PubMed ID: 8951768
[TBL] [Abstract][Full Text] [Related]
27. Defining targets in myeloproliferative disorders: reflecting on what is important.
Griesshammer M
Hematol Oncol; 2009 Jun; 27 Suppl 1():2-4. PubMed ID: 19468984
[TBL] [Abstract][Full Text] [Related]
28. Thrombocytosis in children.
Chiarello P; Magnolia M; Rubino M; Liguori SA; Miniero R
Minerva Pediatr; 2011 Dec; 63(6):507-13. PubMed ID: 22075805
[TBL] [Abstract][Full Text] [Related]
29. [Retrospective analysis of the clinical course of 12 children given the diagnosis essential thrombocythemia].
Kratz CP; Abd El-Monheim A; Manke EM; Rister M; Rogge T; Niemeyer CM
Klin Padiatr; 2004; 216(6):349-55. PubMed ID: 15565550
[TBL] [Abstract][Full Text] [Related]
30. Simultaneous study of platelets and phagocytes in myeloproliferative disorders.
Laharrague PF; Corberand JX; Fillola G; Boneu BP; Pris JF
Biomed Pharmacother; 1984; 38(9-10):462-5. PubMed ID: 6597727
[TBL] [Abstract][Full Text] [Related]
31. Advances in the molecular characterization of Philadelphia-negative chronic myeloproliferative disorders.
Pikman Y; Levine RL
Curr Opin Oncol; 2007 Nov; 19(6):628-34. PubMed ID: 17906464
[TBL] [Abstract][Full Text] [Related]
32. Erythromelalgia--a thrombotic complication in chronic myeloproliferative disorders.
Tarach JS; Nowicka-Tarach BM; Matuszek B; Nowakowski A
Med Sci Monit; 2000; 6(1):204-8. PubMed ID: 11208311
[TBL] [Abstract][Full Text] [Related]
33. Bone marrow histopathology in the diagnosis of chronic myeloproliferative disorders: a forgotten pearl.
Thiele J; Kvasnicka HM; Vardiman J
Best Pract Res Clin Haematol; 2006; 19(3):413-37. PubMed ID: 16781481
[TBL] [Abstract][Full Text] [Related]
34. [C-reactive protein in differential diagnosis of primary thrombocytosis].
Pérez Encinas MM; Bello López JL; Pérez Crespo S; Lete Achirica I
Med Clin (Barc); 1995 Apr; 104(12):441-3. PubMed ID: 7739278
[TBL] [Abstract][Full Text] [Related]
35. Essential thrombocythemia.
Finazzi G; Harrison C
Semin Hematol; 2005 Oct; 42(4):230-8. PubMed ID: 16210036
[TBL] [Abstract][Full Text] [Related]
36. [Diagnosis and treatment of essential thrombocythemia].
Kuramoto A
Rinsho Ketsueki; 1995 May; 36(5):480-6. PubMed ID: 7783354
[TBL] [Abstract][Full Text] [Related]
37. Clinical, pathological and molecular features of the chronic myeloproliferative disorders: MPD 2005 and beyond.
Michiels JJ
Hematology; 2005; 10 Suppl 1():215-23. PubMed ID: 16188676
[TBL] [Abstract][Full Text] [Related]
38. The 2008 World Health Organization classification system for myeloproliferative neoplasms: order out of chaos.
Tefferi A; Thiele J; Vardiman JW
Cancer; 2009 Sep; 115(17):3842-7. PubMed ID: 19472396
[TBL] [Abstract][Full Text] [Related]
39. Thrombosis and bleeding in polycythemia vera and essential thrombocythemia: pathogenetic mechanisms and prevention.
Landolfi R; Cipriani MC; Novarese L
Best Pract Res Clin Haematol; 2006; 19(3):617-33. PubMed ID: 16781491
[TBL] [Abstract][Full Text] [Related]
40. Anagrelide for control of thrombocytosis due to myeloproliferative disorders.
Harrison CN
Future Oncol; 2005 Oct; 1(5):609-18. PubMed ID: 16556037
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]